ABT751 clinical trials
Also written ABT-751.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2002
How each study uses ABT751 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ABT-751
- 11
Studies by the year they started
12 studies that test it; most in 2002 (3)
| Year | Studies |
|---|---|
| 2002 | 3 |
| 2003 | 3 |
| 2004 | 2 |
| 2006 | 2 |
| 2007 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 6
Abbott (5) · Children's Oncology Group (1) · M.D. Anderson Cancer Center (1) · AbbVie (prior sponsor, Abbott) (1) · National Institutes of Health Clinical Center (CC) (1) · Therapeutic Advances in Childhood Leukemia Consortium (1) · Konstantin Dragnev (1) · Vanderbilt-Ingram Cancer Center (1)
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic agents source
Studies
Open first, then newest update. How each study uses ABT751 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- ABT-751 With Chemotherapy for Relapsed Pediatric ALLTerminatedPhase 1/2Therapeutic Advances in Childhood Leukemia ConsortiumNCT00439296Written as ABT-751
- ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous TreatmentCompletedPhase 2Children's Oncology GroupNCT00436852Written as ABT-751
- Study of ABT-751 in Patients With Refractory Hematologic MalignanciesCompletedPhase 1M.D. Anderson Cancer CenterNCT00047489Written as ABT-751
- Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung CancerTerminatedPhase 1/2Konstantin DragnevNCT00735878Written as ABT-751 and Carboplatin
- A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung CancerCompletedPhase 1/2AbbVie (prior sponsor, Abbott)NCT00297089Written as ABT-751
- ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyTerminatedPhase 1/2Vanderbilt-Ingram Cancer CenterNCT00471718Written as ABT-751
- ABT-751 in Treating Young Patients With Refractory Solid TumorsCompletedPhase 1National Institutes of Health Clinical Center (CC)NCT00036959Written as ABT-751
- A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung CancerTerminatedPhase 1/2AbbottNCT00354562Written as ABT-751
- A Study of ABT-751 in Patients With Renal Cell CancerCompletedPhase 2AbbottNCT00073112Written as ABT-751
- A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.CompletedPhase 2AbbottNCT00063102Written as ABT-751
- A Study of ABT-751 in Patients With Colorectal CancerCompletedPhase 2AbbottNCT00073138Written as ABT-751
- A Study of ABT-751 in Patients With Non-Small Cell Lung CancerCompletedPhase 2AbbottNCT00073151Written as ABT-751